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Abstract
Cardiac remodelling with interstitial ﬁbrosis in renal failure, which so far is only
poorly understood on the molecular level, was investigated in the rat model by a global
gene expression proﬁling analysis. Sprague–Dawley rats were subjected to subtotal
nephrectomy (SNX) or sham operation (sham) and followed for 2 and 12 weeks,
respectively. Heart-speciﬁc gene expression proﬁling, with RZPD Rat Unigene-1
cDNA arrays containing about 27000 gene and EST sequences revealed substantial
changes in gene expression in SNX compared to sham animals. Motor protein genes,
growth and differentiation markers, and extracellular matrix genes were upregulated
in SNX rats. Obviously, not only genes involved in cardiomyocyte hypertrophy, but
also genes involved in the expansion of non-vascular interstitial tissue are activated
very early in animals with renal failure. Together with earlier ﬁndings in the SNX
model, the present data suggest the hypothesis that the local renin–angiotensin system
(RAS) may be activated by at least two pathways: (a) via second messengers and G-
proteins (short-term signalling); and (b) via motor proteins, actins and integrins (long-
term signalling). The study documents that complex hybridization analysis yields
reproducible and promising results of patterns of gene activation pointing to signalling
pathways involved in cardiac remodelling in renal failure. The complete array data
are available via http://www.rzpd.de/cgi-bin/services/exp/viewExpressionData.pl.cgi
Copyright  2003 John Wiley & Sons, Ltd.
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Introduction
Death from cardiac causes is up to 20 times more
frequent in patients with renal failure than in the
background population (Raine et al., 1992; US
Renal Data System, 1995). Patients with renal fail-
ure are the group with the highest known cardiovas-
cular risk. There is increasing evidence that such a
risk is not unique to endstage renal failure, but may
occur very early on in the course of renal disease
(Sharma et al., 1996). The cardiovascular lesions
include complex cardiac remodelling affecting not
only contractile parenchyma with development of
left ventricular hypertrophy (LVH), but also vascu-
lar and interstitial tissue (Amann and Ritz, 1997,
2001).
Cardiac remodelling in renal failure is of inter-
est not only because of its clinical relevance, but
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also because it may provide experimental advan-
tages, since the onset of the abnormality is clearly
deﬁned in time and primary manipulations of the
heart are not required. Thus, renal failure may be
a useful model for the more general problem of
identifying mechanisms underlying cardiac remod-
elling. The exact nature of these cardiac-speciﬁc
structural alterations have been characterized in
detail in patients with renal failure (Amann et al.,
1998) and particularly in the animal model of
the subtotally nephrectomized rat (SNX), which
is a well-accepted model of moderate renal fail-
ure (Amann and Ritz, 1997; Amann et al., 1998,
2000; Nabokov et al., 1999). Using immunohisto-
chemistry, in situ hybridization and speciﬁc inter-
ventions, evidence for a pathophysiological role
of the renin–angiotensin (RAS) and the endothe-
lin (ET-1) system has been found (Amann et al.,
2000; Nabokov et al., 1999; Wessels et al, 1999).
In addition, increased expression of growth factors
and alteration in the extracellular matrix has been
documented (Amann et al., 1998).
It was the aim of the present study to: (a) investi-
gate changes in cardiac gene expression with par-
ticular focus on ﬁbrosis in the SNX model at an
early (2 weeks) and a late time point (12 weeks),
using high-throughput techniques; and (b) to con-




Male 200 g Sprague–Dawley rats were housed in
single cages at constant room temperature (20 ◦C)
and humidity (75%) under a controlled light–dark
cycle. The rats were fed a diet containing 40 g
protein and 0.6 g NaCl per 100 g (Altromin Co.,
Lage/Lippe, Germany). After a 3 day adaptation
period, the animals were randomly allotted to
subtotal nephrectomy (SNX, n = 20) or sham
operation (sham, n = 20), which were performed
as follows. In a ﬁrst operation the right kidney
was removed under general anaesthesia (ketamin,
xylazin) and weighed. The sham operation con-
sisted of decapsulation of the kidney, taking special
care not to damage the adrenals. After 1 week, the
SNX was completed by resecting the lower and
upper poles of the meanwhile hypertrophied left
kidney. In order to standardize the procedure, a def-
inite amount of cortex corresponding to 75% of the
weight of the resected right kidney was removed
(Amann and Ritz, 1997; Amann et al., 1998, 2000;
Nabokov et al., 1999). The sham operation was
performed as described above. This two-step surgi-
cal resection of the renal cortex leads to a moderate
and very stable course of renal failure with no or
only a very mild increase in systolic blood pressure
and associated structural cardiovascular alterations,
which have been extensively characterized in previ-
ous studies (Amann and Ritz, 1997; Amann et al.,
1998, 2000; Nabokov et al., 1999).
Perfusion ﬁxation, RNA isolation,
immunohistochemistry and in situ
hybridization
After 2 and 12 weeks, respectively, the experiment
was terminated by retrograde perfusion ﬁxation
via the abdominal aorta in 10 SNX and 10 sham
animals, as described in detail elsewhere (Amann
and Ritz, 1997; Amann et al., 1998, 2000; Nabokov
et al., 1999). Five SNX and ﬁve sham animals
were perfused using ice-cold NaCl for molecular
biology purposes; for the remaining animals 3%
glutaraldehyde was used as ﬁxative.
Small pieces of the hearts of ﬁve animals per
group and time point were homogenized, using a
dismembrator (Braun Co, Melsungen, Germany).
Total RNA was isolated in each case, using the
single-step RNA isolation method (Chomczyn-
ski and Sacchi, 1987) with Trizol (Invitrogen
Co., Germany). Poly(A)+ RNA was isolated from
total RNA, using Dynabeads (Dynal Co., Ger-
many) according to the manufacturer’s manual. The
remaining heart was cut into transverse sections
and ﬁxed with formaldehyde or isopentane for mor-
phological, immunohistological and molecular bio-
logical investigations. Immunohistochemical inves-
tigations were performed using the avidin–biotin
method, as described in detail by Amann et al.
(1998). Non-radioacitve in situ hybridization for
angiotensinogen, ET-1, renin and TGF-β was per-
formed as described in detail elsewhere (Amann
et al., 1998, 2000; Nabokov et al., 1999).
Rat unigene-1 cDNA array
The Rat unigene-1 array contains 27 350 cDNA
clones of the Bento Soares clone collection
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(University of Iowa). The cDNA products were
PCR-ampliﬁed, using M13 forward and reverse
standard primers, and spotted onto a 22 × 22 cm
nylon membrane in a 5 × 5 pattern (RZPD Berlin).
For details of the methods, see Boer et al. (2001).
Each 5 × 5 ﬁeld contained 12 genes spotted in
duplicate and one PCR fragment representing the
Escherichia coli kanamycin resistance gene. This
spot was used as the ‘empty’ spot for background
subtraction during data analysis (see below). For
quality control, M13 forward and reverse primers
were end-labelled with 33P γ-ATP and hybridized
to each membrane to verify that all ﬁlters from
the same robot run were spotted evenly and com-
pletely. After quality control, the membranes were
stripped and used for complex hybridizations after
about 6 weeks. Only ﬁlters from the same robot
run containing comparable concentrations of PCR
products representing single genes or ESTs were
used for hybridization with the two different sam-
ples (sham, SNX; see below). The individual exper-
iments — 2w (2 weeks after operation, see below)
and 12w (12 weeks after operation, see below) as
well as repetitions — were performed with differ-
ent ﬁlter batches.
Hybridization of global rat arrays and image
analysis
The whole hybridization procedure was done
according to Boer et al. (2001). 500–1000 ng
poly(A)+ RNA was reverse transcribed using
(dT)18 primer and 33P α-dCTP without ampli-
ﬁcation and puriﬁed. The labelled cDNA was
hybridized to the rat unigene-1 array. The hybridi-
zation solution contained 6× SSC/5 x Denhardt’s,
with Cot-1 DNA (Invitrogen, Germany) and (dA)40
oligonucleotide for blocking. After exposition of
the hybridized membranes, the PhosphorImager
screens were scanned (Fuji FLA-3000, 100 µmr e s -
olution; Fuji BAS-reader software). The primary
image analysis (estimation of nVol grey level val-
ues for each individual spot) was done using the
ArrayVision software package (Interfocus), which
had been adjusted to the 5 × 5 array before. The
background was corrected locally in each 5 × 5
ﬁeld by subtracting the empty spot signal. Normal-
ization was done via the average signal intensity
(without empty spots) on the whole membrane.
The ratio of the spot-to-spot comparison was taken
for further analysis; those values close to zero
(smaller than 0.001) were eliminated. Since each
PCR fragment was spotted twice on each mem-
brane, and each hybridization experiment was per-
formed twice, four ratios were entered into our
database tool (Access database program, Microsoft)
to make an analysis in a non-statistical manner:
three out of four ratios (one outlier was accepted)
had to show the same tendency to be included in
the ﬁnal list. For each experiment, two indepen-
dent hybridizations with ﬁve animals per time point
were performed.
Results
Cardiac structural alterations in the rat model
of subtotal nephrectomy
We found evidence for activation of ﬁbrotic and
hypertrophic pathways at different time points after
the induction of renal failure in the rat model of
subtotal nephrectomy.
It is well known from several previous stud-
ies using exactly the same animal model that
after 2 weeks of renal failure no increase in blood
pressure and only a moderate increase in left
ventricular weight are observed, whereas activa-
tion of interstitial cells is already present (Amann
et al., 1994). Afterwards, left ventricular weight
increases progressively, leading to marked LVH
after 8 and 12 weeks (Amann et al., 1998, 2000;
Nabokov et al., 1999). The animals do not, how-
ever, develop marked hypertension or anaemia,
and plasma renin activation is low, which is in
contrast to other models of renal failure (Amann
et al., 1994, 1997, 1998, 2000, 2001). Treatment of
subtotally nephrectomized rats using sympatholytic
agents provided some indirect evidence of a poten-
tial activation of the sympathetic nervous system;
there is no deﬁnite data, however (Amann et al.,
2001).
At 8 weeks, LVH of renal failure is accompa-
nied by a signiﬁcant increase in myocyte diameter,
activation and expansion of the non-vascular inter-
stitial tissue, a decrease in capillary density and an
increase in wall thickness of small intramyocardial
arterioles (Figure 1A, B; Amann and Ritz, 1997,
2001; Amann et al., 1997, 1998, 2000; Nabokov
et al., 1999). Due to this time dependency of car-
diac lesions, we decided to investigate an early
(2 weeks) and a late (12 weeks) time point.
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Figure 1. Typical morphologicalchangesof the myocardium after 2 (A, B) and12 weeks(C, D) of renalfailure.Hypertrophy
of cardiomyocytes, activation of the non-vascular interstitium (arrow) and arteriolar wall thickening is clearly visible in
subtotally nephrectomized rats (D) at week 12 compared to sham-operated controls (C)
Analysis of differentially regulated genes
We were especially interested in extracellular
matrix (ECM) genes and in molecules possibly
involved in promoting ECM formation. Therefore,
for data mining from gene expression proﬁling
experiments, the genes were grouped as follows:
1. Members of the renin–angiotensin system
(RAS) as the potentially most important partic-
ipating hormone system.
2. Members of the group of ECM genes.
3. Genes involved in the regulation of cell junc-
tions (adhesion molecules or structural pro-
teins).
4. Genes involved in cell signalling (G-proteins,
MAP/ERK cascade, second messenger).
5. Members of the cytoskeleton (structural pro-
teins, motor proteins).
6. Growth factors.
Genes and ESTs belonging to these groups were
classiﬁed according to the GeneCards database
(Weizmann Institute; http://bioinformatics.weiz-
mann.ac.il/cards/) and the literature (Figure 2).
Altogether, about 400 regulated genes potentially
involved in the above-described cardiac lesions
could be classiﬁed into the selected gene families.
The renin–angiotensin system (RAS) and
downstream pathways are activated in uraemic
cardiac hypertrophy
We found an early upregulation of the endothe-
lin B (ETB) receptor in the hypertrophic heart
after SNX (Figure 2); this ﬁnding was conﬁrmed
by in situ hybridization, documenting increased
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ET-1 mRNA in the heart of SNX after 12 w
(Figure 3H), as well as an earlier study using PCR
(Amann et al., 2000). In addition, using in situ
hybridization we found increased expression of
renin (Wessels et al., 1999) and angiotensinogen
RNA in the heart of SNX (Figure 3D) compared
to controls (Figure 3C), indicating activation of the
local RAS. Moreover, expression of TGF-β mRNA
was markedly higher in the heart of SNX rats
(Figure 3F) compared to controls (Figure 3E).
G-proteins, second messengers and motor
proteins as potential signal mediators
Since the 7-transmembrane receptor ETB is cou-
pled to further effector systems by nucleotide reg-
ulatory proteins (Douglas and Ohlstein, 1997), we
focused on this group of proteins in our analysis
and also on second messengers as further down-
stream molecules. We found downregulation of
cdc42 after 2 w, and upregulation of two RAC
clones (12 w) of RHO B (2 w) and ESTs simi-
lar to RHO C and RHO A (12 w). This makes
sense, because focal adhesion assembly is mainly
mediated by cdc42, RAC and members of the Ras
superfamily of small GTP-binding proteins and
other effectors (Cau et al., 2001; Krendel et al.,
2002; Schoenwaelder and Burridge, 1999). C-JUN,
another signalling molecule, was not differentially
regulated in the present model. P38 mitogen-
activated protein kinase (MAPK), an important
member of the cytoplasmic mitogen-activated pro-
tein kinase/extracellular-signal regulated kinases
(MAP/ERK), showed controversial results: One
clone was upregulated after 2 w, which would ﬁt
to the well known ETB receptor-dependent acti-
vation (Cattaruzza et al., 2001), whereas another
clone was downregulated after 2 and 12 w, respec-
tively. A marked regulation of protein kinase C and
associated molecules (20 clones), inositol kinases
(eight clones), phosphatases (ﬁve clones) and phos-
pholipase C (11 clones) points to a major role of
these genes in LVH.
There is convincing evidence that motor pro-
teins are involved in the formation of focal
adhesions, integrin assembly and ECM formation
(Burridge and Chrzanowska-Wodnicka, 1996). We
obtained some expected results from our complex
hybridizations: 30 myosin clones were differen-
tially regulated, 10 clones (four of them encod-
ing myosin light chains) downregulated after 2 w,
13 clones upregulated and eight clones downreg-
ulated after 12 w. Of the 12 dynein clones, three
went down after 2 w and four after 12 w (three
of them are ESTs), whereas ﬁve were upregulated
after 12 w. With kinesin, the result was as fol-
lows: two clones (kinesin-related protein) down in
2 w, eight clones up in 12 w, two clones down in
12 w. The predominant upregulation of some of
the cytoskeleton-related proteins at 12 w might be
initiated by LIM proteins (Khurana et al., 2002).
The extracellular matrix (ECM) accumulates
during cardiac remodelling
As a central linker protein between the cytoplasm
and the extracellular matrix, we found integrin-β1
to be upregulated, especially in the 12 w sample
(Figure 2). This result was conﬁrmed by immuno-
histochemistry (Figure 3A, B; Amann et al., 1998).
28 clones of the 128 ECM-linked clones listed in
Figure 1 code for collagen subunits or enzymes
involved in collagen turnover. Most genes were
upregulated after 2 w, and no further change was
detected after 12 w. However, single clones were
upregulated after 12 w, one being a collagenase
(UMCase). This indicates that collagen turnover
continues at a somewhat lower level after 2 w.
Two procollagens even appear to be downregulated
after 2 and 12 w, respectively, whereas another
clone (procollagen C-proteinase enhancer protein,
PCOLCE) was upregulated after 2 and 12 w. A
number of proteoglycans, another important group
involved in ECM metabolism, were also upregu-
lated as early as 2 w after SNX. Several SPARC
clones were downregulated, which is in agreement
with other ﬁndings (Schoenwaelder and Burridge,
1999). Other mediators of ECM formation found to
be upregulated were tissue inhibitor of metallopro-
teinase 3 (TIMP3) at 2 w and 12 w, matrix met-
alloproteinase 7 (MMP7) at 2 w, laminins (eight
clones) at 12 w, plectin (three clones) at 12 w, cell
adhesion kinase β at 12 w, and N-cadherins and
catenins.
Discussion
Renal failure is associated with complex cardiac
remodelling that occurs very early on in the course
of the disease (Parfrey et al., 1996; Stefanski et al.,
1996) and it is characterized by LVH with accom-
panying changes in the myocardial composition,
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Figure 2. Summary of differentially regulated genes belonging to gene families investigated in this study. Red, clones
upregulated in SNX vs. sham (2 weeks/12 weeks); green, clones downregulated in SNX vs. sham (2 weeks/12 weeks). The
gene names are given according to the UniGene database. Further information concerning the listed genes is accessible
with the RZPD clone ID via the RZPD database (www.rzpd.de) or other databases
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Figure 2. Continued
i.e. interstitial ﬁbrosis and impaired microcircula-
tion. Activation and expansion of cardiac interstitial
tissue is an important hallmark of cardiac remod-
elling in uraemic patients and in rats with renal
failure (Amann and Ritz, 1997; Amann et al., 1994;
Mall et al., 1990). Using electron microscopy, acti-
vation and enlargement of interstitial ﬁbroblasts
was seen as early as 2 weeks after SNX (Amann
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Figure 3. Representative immunohistological and in situ hybridization data. (A, B) Integrin-β1 protein expression is higher
in the heart of a subtotally nephrectomized rat (B) compared to a sham-operated control animal (A). C–H: in situ analysis
of angiotensinogen (C, D), TGF-β1 (E, F) and endothelin-1 (G, H) mRNA expression by non-radioactive in situ hybridization
in sham-operated (C, E, G) and subtotally nephrectomized rats (D, F, H). mRNA expression of all three genes is increased
in the heart in renal failure
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et al., 1994). Interestingly, this was not seen in
other experimental models of cardiac hypertrophy,
i.e. the spontaneously hypertensive rat (SHR) or the
1C-2K rat with renovascular hypertension (Amann
et al., 1994; 1998). The pathophysiology of these
cardiac alterations is still not clear; however, earlier
studies found some evidence for a pathophysiolog-
ical role of the RAS and the ET system (Amann
and Ritz, 1997, 2001; Amann et al., 1998; Wessels
et al., 1999).
In the present study, we investigated differential
gene expression in the course of cardiac remod-
elling in experimental renal failure using cDNA
array technology. We found an early upregulation
of several groups of genes known to be involved
in ECM production and remodelling, i.e. colla-
gens, proteoglycans, laminin and connected linker
molecules. Some of the results of the present study
are in agreement with earlier immunohistochemi-
cal and molecular biological studies in the heart of
SNX animals of renal failure (Amann et al., 1998;
Wessels et al., 1999), or were conﬁrmed by other
assays (Figure 3).
Potential links from the RAS to the
extracellular matrix via G-proteins, second
messengers and cytoskeleton
In a previous study using in situ hybridization
we found increased cardiac renin, angiotensino-
gen and preproendothelin mRNA after induction of
renal failure (Amann and Ritz, 1997; Amann et al.,
2000). An important role of the RAS in cardio-
vascular remodelling, in particular cardiac ﬁbrosis,
has been documented by experimental and clini-
cal studies (Brilla, 2000). In the present study, we
found evidence for an early upregulation of the ETB
receptor in the hearts of SNX after 2 w. The ETB
receptor is predominantly located on endothelial
cells and is known to be upregulated in LVH in a G
protein-dependent manner (Douglas and Ohlstein,
1997; Zolk et al., 2002).
Therefore, as shown for the kidney, several spe-
ciﬁc ET responses apparently exist in the heart
(Nambi et al., 2001) which represent not only a
prohypertrophic stimulus for cardiomyocytes but
also stimulate ﬁbroblasts (Tsuruda et al., 2002)
and vascular smooth muscle cells (VSMC; Giulu-
mian et al., 2002), as indicated by earlier studies
using ET-receptor blockers (Amann et al., 2000;
Nabokov et al., 1999).
We found strong evidence for upregulation of
several second messenger molecules, i.e. protein
kinase C and associated molecules, the phos-
phatidylinositol pathway, phosphoinositide 3-ki-
nase (PI3K) and phosphoinositide 5-kinase (PI5K),
which are known to be connected with actin
ﬁlament formation (Hartwig et al., 1995; Keely
et al., 1997). Interestingly, an increased intersti-
tial expression of integrin-β1 after SNX (Figure 2;
Amann et al., 1998) conﬁrms its central role in
ECM formation and also its mediating function by
binding to actin stress ﬁbres.
Since we do not ﬁnd a remarkable upregula-
tion of actin genes, it remains to be investigated
whether actin stress ﬁbre formation can directly
be correlated to the increase of second messen-
gers and integrins that we found. We also postulate
an important role for phosphorylation and dephos-
phorylation of phosphatidylinositol in regulation of
cardiac remodelling in LVH. This hypothesis will
need to be conﬁrmed using more specialized phos-
phorylation assays.
Motor proteins play a potential role in signal
translation
There is strong experimental evidence that motor
proteins are involved in the formation of focal
adhesions, integrin assembly and ECM forma-
tion, e.g. it has been found that myotonic dystro-
phy kinase related cdc42-binding kinase (MRCK)
phosphorylates myosin light chains (Leung et al.,
1998). Myosin light chain phosphorylation pro-
motes both myosin ﬁlament assembly and actin-
activated myosin ATPase activity (Burridge et al.,
1996). These effects result in bundling of actin
ﬁlaments. The resulting tension is transmitted to
integrins, which cluster in a characteristic fashion
(Chrzanowska-Wodnicka and Burridge, 1996). As
expected, it is mainly the expression of myosin
genes and of genes coding for associated proteins,
as well as other motor proteins, that are regu-
lated in our experiments. We are currently not able
to address any signalling function for dynein and
kinesin, but they function as transporters along
microtubules and are co-localized with or linked
to actin ﬁbres via further linker molecules, respec-
tively (Oakley and Brunette, 1995).
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Two potential pathways are leading to ECM
formation in hearts of renal failure
Whereas most of the collagens and proteoglycans
are upregulated during the ﬁrst days after opera-
tion, in the 12 w group a striking upregulation of
laminins, together with integrins, is noted. In par-
ticular, integrin is thought to be a central player
because of its inﬂuence on RHO family GTPases.
Structural cytoskeletal proteins again are mediators
of integrin clustering and microtubule polymeriza-
tion is affected by RHO A (Schoenwaelder and
Burridge, 1999). We conclude from our results that
at least two pathways for ECM remodelling are
operative. They both start with activation of the
RAS. Subsequently, either G-proteins and second
messengers are activated (short-term signalling) or
motor proteins, actins and integrins are upregulated
(long-term signalling; Figure 4).
Many other genes remain to be investigated
Some upregulated ECM genes discussed here were
also identiﬁed by expression proﬁling of human
hypertrophied cardiac tissue, e.g. myosin regula-
tory light chains, troponin and desmin (Hwang
et al., 2000); it should be mentioned, however, that
many other molecules appear to be regulated and
have to be investigated in further detail. Examples
include the TIMP and MMP proteins, which were
shown to be important regulators and mediators
of renal ﬁbrosis via induction of aldosterone and
angiotensin II (ANGII) (Papakonstantinou et al.,
2001). They were not addressed in the present
experiment and have to be investigated in further
studies.
Furthermore, members of other gene families are
obviously regulated and are potentially involved in
cardiac remodelling as shown by us, and others
(Hwang et al., 2000, 2002). CD59 is an 18–20 kDa
GPI-anchored membrane protein that functions as
a key regulator of the terminal step of the com-
plement activation cascade. It restricts binding
of C9 to the C5b-8 complex, thereby preventing
the formation of the membrane attack complex.
The rat analogue of human CD59 (protectin) is
expressed in the sarcolemmal membranes of nor-
mal cardiomyocytes as an important sarcolemmal
Figure 4. Schematic summary of postulated pathways involved in cardiac remodelling of renal failure
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inhibitor of the complement membrane attack com-
plex (MAC; Vakeva et al., 1994); it is lost, or
downregulated, after ischaemic or hypoxic injury
to the heart (Venugopal et al., 2001). In addition,
in experimental studies it was shown that infusion
or overexpression of CD59 offers a signiﬁcant pro-
tection against complement-mediated myocardial
injuries (Chakraborti et al., 2000; Fisicaro et al.,
2000).
Lipoprotein lipase (LPL) of either VSMC or
macrophage origin is an endothelial-bound enzyme
that is rate determining for the clearance of
triacylglycerol-rich lipoproteins. It is known to
accelerate atherosclerosis (Esenabhalu et al., 2002;
Wilson et al., 2001), is upregulated in cardiomy-
ocytes by insulin (Ewart et al., 1999) and its
heparin-releasable LPL activity was higher in the
heart of rats with moderate, but not severe, diabetes
(Rodrigues et al., 1997).
Heat shock proteins (HSPs) are well known for
their ability to ‘protect’ the structure and func-
tion of native macromolecules, particularly as they
trafﬁc across membranes. Some of them (HSP27,
HSP72, HSP60) have been shown to be upreg-
ulated after cardiac ischaemic/hypoxic injury in
order to offer cardioprotection against ischaemic
injury by induction of antiapoptotic effects via
interaction with bax and/or bak pathways (Kirch-
hoff et al., 2002; Lin et al., 2001).
Plasminogen activator inhibitor-1 (PAI-1) is a
major anti-ﬁbrinolytic glycoprotein thought to pro-
mote vascular growth and ﬁbrosis during vari-
ous pathophysiological situations (Venugopal et al.,
2001). In particular, it was shown that aldosterone
interacts with ANG II to increase PAI-1 expres-
sion in vitro and in vivo. PAI-1, by inhibiting the
production of plasmin from plasminogen, tips the
balance in favour of ECM accumulation, thereby
promoting ﬁbrosis (Brown et al., 2002).
Ubiquitin, a so-called repair-related protein, is
upregulated in the heart early after injury (Ishikawa
et al., 2000), particularly in post-ischaemic recov-
ery (Sharma et al., 1996). In addition, the ubiqui-
tin/proteasome system represents the cell’s major
tool for extralysosomal protein degradation, reg-
ulating a variety of different processes, such as
proliferation, differentiation, cell cycling and apop-
tosis. Because both negative and positive regulators
of proliferation and apoptosis undergo proteasomal
degradation in a tightly regulated and temporally
controlled fashion, the 26S proteasome can play
opposite roles in the regulation of proliferation and
apoptosis (Naujokat and Hoffmann, 2002).
Calcyclin, a member of the S100 protein family
of Ca-binding proteins, is expressed in human
epithelial cells and ﬁbroblasts of several organs,
indicating that it is related either to proliferation
rate or secretion activity (Kuznicki et al., 1992).
Although not much is known about the speciﬁc role
of calcyclin in the heart, Ca-binding proteins play
a critical role in cardiomyocyte function regulating
sarcoplasmic reticulum Ca2+ handling (McMahon
et al., 2002).
We plan to investigate the signalling pathways
leading to ECM formation in more detail. Cur-
rently, we are performing cDNA sub-arrays on
glass slides and nylon membranes, respectively,
containing clones which represent about 1000
genes potentially involved in LVH, and about 100
‘housekeeping’ genes as controls. With this array,
which contains only resequenced clones, we are
more ﬂexible than with the global array, in that
we can reach a higher sensitivity and can repeat
the same experiment several times, which should
enable us to detect changes even in genes with low
expression.
We further intend to investigate samples obtained
at other time points in the course of renal failure,
to better characterize the time course. Furthermore,
the similarities or differences to other models of
LVH and the effect of various treatments will be
studied. Proteomic assays, especially those looking
for protein modiﬁcations such as phosphorylations,
are under way and should allow us to obtain further
insights into the molecular processes involved in
cardiac remodelling in renal failure.
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